Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Innate immunity contributes to the pathogenesis of autoimmune diseases, such as type 1 diabetes, but until now no randomised, controlled trials of blockade of the key innate immune mediator interleukin-1 have been done. We aimed to assess whether canakinumab, a human monoclonal anti-interleukin-1 antibody, or anakinra, a human interleukin-1 receptor antagonist, improved β-cell function in recent-onset type 1 diabetes.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Lancet |
Vol/bind | 381 |
Udgave nummer | 9881 |
Sider (fra-til) | 1905-15 |
Antal sider | 11 |
ISSN | 0140-6736 |
DOI | |
Status | Udgivet - 1 jun. 2013 |
ID: 96512501